FDA says clinical data for UniQure's Huntington's disease therapy not adequate

Core Viewpoint - UniQure's experimental gene therapy for Huntington's disease lacks sufficient clinical data to support its marketing application as per the U.S. Food and Drug Administration [1] Group 1 - The gene therapy in question is aimed at treating Huntington's disease [1] - The U.S. FDA has indicated that the clinical data provided by UniQure is inadequate for the marketing application [1]